查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2104682

全球液態生物檢體市場：機會與策略展望（至2035年）

Lung Cancer Liquid Biopsy Global Market Opportunities And Strategies To 2035
出版日期: | 出版商: The Business Research Company | 英文 373 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

2020 年全球肺癌液態生物檢體市場價值 3.619 億美元，預計到 2025 年將以超過 25.00% 的複合年成長率成長。

肺癌液態生物檢體是一種微創診斷技術，它透過分析循環腫瘤DNA (ctDNA)、循環性腫瘤細胞(CTC) 和其他主要存在於後續觀察等體液中的生物標記等腫瘤衍生質能，來檢測和監測肺癌。該市場涵蓋了生物技術公司、診斷檢測實驗室和醫療機構等營業單位所產生的收入，這些實體開發並提供基於液態生物檢體的肺癌診斷和治療產品和服務。腫瘤科醫師、病理學家和醫療保健專業人員會將這些檢測用於疑似肺癌患者、正在接受治療的患者以及接受治療後後續觀察的患者。

肺癌液態生物檢體市場涵蓋了提供用於肺癌液態生物檢體檢測和管理的產品和服務的營業單位（包括機構、個體戶和夥伴關係）的銷售額。這些產品和服務包括儀器、耗材、試劑盒、試劑以及軟體和相關服務。這些解決方案支援檢體採集和處理、檢測方法開發和測試、數據分析和解讀以及臨床決策支援等各個階段，並基於次世代定序(NGS) 和聚合酵素鏈鎖反應(PCR) 等技術。

吸煙率和煙草消費量高

歷史上，高吸菸率和菸草消費推動了肺癌液態生物檢體市場的成長。菸草的廣泛使用增加了肺癌的發生率，從而產生了對高效早期診斷解決方案的強烈需求。醫療專業人員越來越關注液態生物檢體技術，將其作為一種非侵入性方法來檢測和監測癌症，尤其是在長期吸菸者等高風險族群中。此外，人們對吸菸相關健康風險的認知不斷提高，促使更多人接受篩檢。例如，根據總部位於法國的政府間國際組織－經濟合作暨發展組織（OECD）的數據，截至2025年11月，2023年15歲以上人口的每日吸菸率為14.8%。每日吸菸者比例最高的國家是土耳其、匈牙利、希臘，以及候選成員/夥伴國印尼、保加利亞和中國，這些國家至少有四分之一的人口每日吸菸。 2023年，平均而言，18.5%的男性每天吸煙，而女性的比例為11.4%。因此，高吸菸率和大量的菸草消費推動了液態生物檢體市場的成長。

利用ctDNA即時最佳化癌症治療的適應性免疫療法取得了進展

肺癌液態生物檢體市場的領導者正利用循環腫瘤DNA (ctDNA)推進精準腫瘤學解決方案，實現即時治療監測、自適應免疫療法策略和更精準的患者分層，從而改善臨床療效並實現個人化癌症治療。例如，2025年12月，美國生物技術公司癌症研究所(Cancer Research Institute)啟動了BR.36 II/III期臨床試驗的下一階段，該試驗利用美國醫療保健公司Labcorp Holdings Inc.的液態生物檢體技術，引領進行性肺癌的精準免疫治療。這項研究利用循環腫瘤DNA (ctDNA)監測早期治療反應並據此調整治療方案。疾病進展高風險的患者可能接受免疫療法和化療的合併治療，進而改善個人化醫療策略。這項由包括約翰霍普金斯大學金梅爾癌症中心在內的多家領先研究機構主導的臨床試驗旨在改善治療效果，並將ctDNA確立為即時癌症管理的關鍵工具。

全球肺癌液態生物檢體市場集中度較高，主要由幾家大型企業主導。到了2024年，排名前十的大型企業佔28.08%的市場。

目錄

第1章執行摘要

第2章 目錄

第3章表格一覽

第4章：圖表一覽

第5章：報告結構

第6章 市場特徵

  • 市場的一般定義
  • 概述
  • 肺癌液態生物檢體市場：定義和細分
  • 市場區隔：依產品（儀器、耗材、試劑盒及試劑、軟體及服務）
  • 市場區隔：依技術分類（多代並行擴展（NGS）和單代擴展（PCR 微陣列））
  • 市場區隔：依生物標記分類（循環腫瘤DNA、細胞外囊泡、循環性腫瘤細胞、其他生物標記）
  • 市場區隔：依臨床應用（治療選擇、治療進展監測、癌症早期篩檢、復發監測、其他應用）
  • 市場區隔：依最終使用者分類（診斷與影像中心、醫院、學術與研究機構、其他最終使用者）

第7章 肺癌液態生物檢體市場：主要產品和服務概述

第8章：全球肺癌液態生物檢體市場：吸引力評分及分析

  • 概述：市場吸引力框架
  • 定量評分調查方法
  • 市場吸引力評分及解讀
  • 因素特定評估
    • 成長潛力
    • 競爭環境
    • 戰略適宜性
    • 風險概況
  • 戰略洞察與建議
    • 戰略意義
    • 策略建議

第9章：肺癌液態生物檢體市場：供應鏈分析

  • 供應鏈與生態系概述
    • 資源
    • 製造業
    • 分配
    • 最終用戶

第10章：主要市場趨勢

  • 關鍵科技與未來趨勢
    • 生物技術、基因組學和精準醫療
    • 人工智慧和自主智慧
    • 數位化、雲端運算、巨量資料和網路安全
    • 工業4.0和智慧製造
  • 主要趨勢
    • 利用 ctDNA 作為指標的適應性免疫療法取得了進展，旨在即時最佳化癌症治療。
    • 人們對人工智慧整合的多組體學在檢測微量殘存疾病和監測復發方面的興趣日益濃厚。
    • 戰略重點是人工智慧驅動的早期檢測和基於碎片化的液態生物檢體活體組織切片創新。

第11章：全球肺癌液態生物檢體：成長分析與策略分析框架

  • 全球肺癌液態生物檢體市場：PESTEL 分析
    • 政治的
    • 經濟的
    • 社會的
    • 技術的
    • 環境因素
    • 合法的
  • 最終用戶（B2B）分析
    • 診斷和影像中心
    • 醫院
    • 學術機構與研究中心
    • 其他最終用戶

第12章 全球肺癌液態生物檢體市場：規模與成長分析

  • 2020-2025年市場成長表現
    • 市場促進因素，2020-2025 年
    • 2020-2025年市場限制因素
  • 市場成長預測，2025-2030年，2035年
  • 預測成長要素和促進因素
    • 定量成長要素
    • 促進因素
    • 抑制因子

第13章：全球肺癌液態生物檢體：總潛在市場（TAM）分析

  • 總潛在市場（TAM）的定義與範圍
  • 調查方法和先決條件
    • 可觸及市場總量：肺癌液態生物檢體市場 - B2B
    • TAM比較分析

第14章：全球肺癌液態生物檢體：市場細分

  • 依產品
  • 透過技術
  • 透過生物標記
  • 臨床應用
  • 最終用戶
  • 按類型細分：設備
  • 依類型細分：耗材、試劑盒、試劑
  • 按類型細分：軟體服務

第15章：肺癌液態生物檢體市場：區域與國別分析

第16章 亞太市場

第17章 東南亞市場

第18章：北美市場

第19章 西歐市場

第20章：南美洲市場

第21章：東歐市場

第22章 中東市場

第23章：非洲市場

第24章：競爭格局與公司概況

  • 肺癌液態生物檢體市場：競爭格局和市場佔有率，2024 年
  • 公司簡介
  • F. Hoffmann-La Roche Ltd
  • Qiagen NV
  • Guardant Health Inc
  • Thermo Fisher Scientific Inc
  • Eurofins Scientific SE

第25章：其他大型企業和創新企業

  • NeoGenomics Laboratories Inc.
  • Agilent Technologies Inc.
  • Sysmex Corporation
  • Illumina Inc.
  • Biodesix Inc.
  • SOPHiA GENETICS SA
  • Caris Life Sciences Inc.
  • Natera Inc.
  • Bio-Rad Laboratories Inc.
  • MDxHealth SA
  • Foresight Diagnostics Inc.
  • Myriad Genetics Inc.
  • Menarini Silicon Biosystems Inc.
  • Inivata Ltd.
  • LungLife AI Inc.

第26章：競爭標竿分析

第27章：競爭對手儀錶板

第28章 肺癌液態生物檢體市場：公司評估矩陣

  • 創新與品牌領導者
  • 品牌主導傳統公司
  • 專注於小眾或本地市場的追隨者公司
  • 新興創新者

第29章：肺癌液態生物檢體市場：值得關注的新創公司

第30章 重大併購

  • Abbott Laboratories Acquired Exact Sciences Corporation
  • Veracyte Inc Acquired C2i Genomics Inc
  • Quest Diagnostics Acquired Haystack Oncology

第31章 近期趨勢：肺癌液態生物檢體市場

  • 透過將先進的液態生物檢體整合到臨床研究中，加強精準腫瘤學。
  • 開發用於高級癌症分析的尖端平台

第32章 機遇與策略

  • 2030年全球肺癌液態生物檢體市場：提供新機會的國家
  • 2030年全球肺癌液態生物檢體市場：蘊藏新機會的細分市場
  • 2030年全球肺癌液態生物檢體市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第33章：肺癌液態生物檢體市場：結論與建議

  • 結論
  • 推薦

第34章附錄

簡介目錄
Product Code: HS5MLCLB01_O26Q1

Lung cancer liquid biopsy refers to a minimally invasive diagnostic approach used to detect and monitor lung cancer by analyzing tumor-derived materials, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs) and other biomarkers, in bodily fluids, primarily blood. This market encompasses the revenues generated by entities, including biotechnology companies, diagnostic laboratories and healthcare institutions, that develop and provide liquid biopsy-based products and services for lung cancer diagnosis and management. These tests are used by oncologists, pathologists and healthcare providers for patients suspected of having lung cancer, as well as those undergoing treatment or post-treatment surveillance.

The lung cancer liquid biopsy market consists of sales by entities (organizations, sole traders and partnerships) that provide products and services for the detection and management of lung cancer using liquid biopsy. This includes instruments, consumables, kits and reagents, as well as software and related services. These solutions support various stages such as sample collection and processing, assay development and testing, data analysis and interpretation and clinical decision support and are based on technologies such as next-generation sequencing (NGS) and polymerase chain reaction (PCR).

The global lung cancer liquid biopsy market was valued at $361.9 million in 2020 which grew till 2025 at a compound annual growth rate (CAGR) of more than 25.00%.

High Prevalence Of Smoking And Tobacco Consumption

During historic period, high prevalence of smoking and tobacco consumption supported the growth of the lung cancer liquid biopsy market. Widespread tobacco use increased the incidence of lung cancer, creating a strong demand for efficient and early diagnostic solutions. Healthcare providers increasingly turned to liquid biopsy technologies as a non-invasive method for detecting and monitoring cancer, particularly among high-risk populations such as long-term smokers. Additionally, rising awareness of smoking-related health risks encouraged more individuals to undergo screening. For instance, in November 2025, according to the OECD (Organization for Economic Co-operation and Development), a France-based intergovernmental international organization, 14.8% of people aged 15 and over smoked daily in 2023. The proportion of daily smokers was highest in Turkiye, Hungary and Greece, as well as in accession/partner countries Indonesia, Bulgaria and China, where at least one in four people smoked daily. On average, 18.5% of men smoked daily in 2023 compared to 11.4% of women. Therefore, high prevalence of smoking and tobacco consumption drove the growth of the lung cancer liquid biopsy market.

Advancing ctDNA-Guided Adaptive Immunotherapy For Real-Time Cancer Treatment Optimization

Key players operating in the lung cancer liquid biopsy market are advancing circulating tumor DNA (ctDNA)-driven precision oncology solutions, enabling real-time treatment monitoring, adaptive immunotherapy strategies and improved patient stratification to enhance clinical outcomes and personalized cancer care. For instance, in December 2025, Cancer Research Institute, a US-based biotechnology company, has initiated the next phase of its BR.36 Phase 2/3 clinical trial, leveraging liquid biopsy technology from Labcorp Holdings Inc., a US-based healthcare company, to guide precision immunotherapy for advanced lung cancer. The study uses circulating tumor DNA (ctDNA) to monitor early responses to treatment and adapt therapy accordingly. Patients showing high risk of disease progression may receive a combination of immunotherapy and chemotherapy, improving personalized care strategies. Led by leading research institutions including Johns Hopkins Kimmel Cancer Center, the trial aims to enhance treatment outcomes and establish ctDNA as a key tool in real-time cancer management.

The global lung cancer liquid biopsy market is fairly concentrated, with large players operating in the market. The top 10 competitors in the market made up 28.08% of the total market in 2024.

Lung Cancer Liquid Biopsy Global Market Opportunities And Strategies To 2035 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global lung cancer liquid biopsy market.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Understand how the market is evolving with growth in the number of listed companies, greater focus on ESG and sustainability positioning, increased focus on broadening shareholder base and rising frequency of M&A and corporate restructuring.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for lung cancer liquid biopsy? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The lung cancer liquid biopsy market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider lung cancer liquid biopsy market; and compares it with other markets.

The report covers the following chapters

  • Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segments, key products, supply chain and market attractiveness scoring and analysis.
  • Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
  • Growth Analysis And Strategic Analysis Framework - Analysis on PESTEL, end use industries, market growth rate, global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
  • Global Market Size And Growth: - Global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
  • Regional And Country Analysis: - Historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison by region and country.
  • Market Segmentation: - Contains the market values (2020-2025) (2025-2030, 2035F) and analysis for each segment by product, by technology, by biomarker, by clinical application and by end user in the market. Historic (2020-2025) and forecast (2025-2030) and (2030-2035) market values and growth and market share comparison by region market.
  • Regional Market Size And Growth: - Regional market size (2025), historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
  • Competitive Landscape: - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
  • Other Major And Innovative Companies: - Details on the company profiles of other major and innovative companies in the market.
  • Competitive Benchmarking: - Briefs on the financials comparison between major players in the market.
  • Competitive Dashboard: - Briefs on competitive dashboard of major players.
  • Key Mergers And Acquisitions: - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
  • Recent Developments: - Information on recent developments in the market covered in the report.
  • Market Opportunities And Strategies: Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
  • Conclusions And Recommendations: This section includes recommendations for lung cancer liquid biopsy providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
  • Appendix: - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

  • 1) By Product: Instruments; Consumables, Kits And Reagents; Software And Services
  • 2) By Technology: Multi-Gene-Parallel Analysis (NGS); Single-Gene Analysis (PCR Microarrays)
  • 3) By Biomarker: Circulating Tumor Deoxyribonucleic Acid; Extracellular Vesicles; Circulating Tumor Cells; Other Biomarkers
  • 4) By Clinical Application: Therapy Selection; Treatment Monitoring; Early Cancer Screening; Recurrence Monitoring; Other Applications
  • 5) By End User: Diagnostics And Imaging Centers; Hospitals; Academics And Research Centers; Other End Users
  • Companies Mentioned: F. Hoffmann-La Roche Ltd; QIAGEN NV; Guardant Health Inc; Thermo Fisher Scientific Inc; Eurofins Scientific SE
  • Countries: Australia; China; India; Indonesia; Japan; South Korea; USA; Canada; Mexico; Brazil; France; Germany; UK; Italy; Spain; Russia
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time-series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; lung cancer liquid biopsy indicators comparison.
  • Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

  • 1.1 Dashboard

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

  • 6.1 General Market Definition
  • 6.2 Summary
  • 6.3 Lung Cancer Liquid Biopsy Market Definition And Segmentations
  • 6.4 Market Segmentation By Product (Instruments, Consumables, Kits And Reagents, Software And Services)
  • 6.5 Market Segmentation By Technology (Multi-Gene-Parallel Analysis (NGS) And Single-Gene Analysis (PCR Microarrays))
  • 6.6 Market Segmentation By Biomarker (Circulating Tumor Deoxyribonucleic Acid, Extracellular Vesicles, Circulating Tumor Cells And Other Biomarkers)
  • 6.7 Market Segmentation By Clinical Application (Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring And Other Applications)
  • 6.8 Market Segmentation By End User (Diagnostics And Imaging Centers, Hospitals, Academics And Research Centers And Other End Users)

7 Lung Cancer Liquid Biopsy Market, Overview Of Key Products/Services

8 Global Lung Cancer Liquid Biopsy Market Attractiveness Scoring And Analysis

  • 8.1 Overview Of Market Attractiveness Framework
  • 8.2 Quantitative Scoring Methodology
  • 8.3 Market Attractiveness Scoring And Interpretation
  • 8.4 Factor-Wise Evaluation
    • 8.4.1 Growth Potential
    • 8.4.2 Competitive Dynamics
    • 8.4.3 Strategic Fit
    • 8.4.4 Risk Profile
  • 8.5 Strategic Implications And Recommendations
    • 8.5.1 Strategic Implications
    • 8.5.2 Strategic Recommendations

9 Lung Cancer Liquid Biopsy Market, Supply Chain Analysis

  • 9.1 Overview of the Supply Chain and Ecosystem
    • 9.1.1 Resources
    • 9.1.2 Manufacturers
    • 9.1.3 Distribution
    • 9.1.4 End Users

10 Major Market Trends

  • 10.1 Key Technologies & Future Trends
    • 10.1.1 Biotechnology, Genomics And Precision Medicine
    • 10.1.2 Artificial Intelligence And Autonomous Intelligence
    • 10.1.3 Digitalization, Cloud, Big Data And Cybersecurity
    • 10.1.4 Industry 4.0 And Intelligent Manufacturing
  • 10.2 Major Trends
    • 10.2.1 Advancing ctDNA-Guided Adaptive Immunotherapy For Real-Time Cancer Treatment Optimization
    • 10.2.2 Rising Focus on AI-Integrated Multi-Omics for Minimal Residual Disease Detection and Recurrence Monitoring
    • 10.2.3 Strategic Focus on AI-Driven Early Detection and Fragmentomics-Based Liquid Biopsy Innovations

11 Global Lung Cancer Liquid Biopsy Growth Analysis And Strategic Analysis Framework

  • 11.1 Global Lung Cancer Liquid Biopsy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
    • 11.1.1 Political
    • 11.1.2 Economic
    • 11.1.3 Social
    • 11.1.4 Technological
    • 11.1.5 Environmental
    • 11.1.6 Legal
  • 11.2 End User (B2B) Analysis
    • 11.2.1 Diagnostics And Imaging Centers
    • 11.2.2 Hospitals
    • 11.2.3 Academics And Research Centers
    • 11.2.4 Other End Users

12 Global Lung Cancer Liquid Biopsy Market Size And Growth Analysis

  • 12.1 Historic Market Growth, 2020 - 2025, Value ($ Million)
    • 12.1.1 Market Drivers 2020 - 2025
    • 12.1.2 Market Restraints 2020 - 2025
  • 12.2 Forecast Market Growth, 2025 - 2030, 2035F Value ($ Million)
  • 12.3 Forecast Growth Contributors/Factors
    • 12.3.1 Quantitative Growth Contributors
    • 12.3.2 Drivers
    • 12.3.3 Restraints

13 Global Lung Cancer Liquid Biopsy Total Addressable Market (TAM) Analysis

  • 13.1 Definition And Scope of Total Addressable Market (TAM)
  • 13.2 Methodology And Assumptions
    • 13.2.1 Total Addressable Market for the Lung Cancer Liquid Biopsy Market - Business to Business (B2B)
    • 13.2.2 TAM Comparison Analysis

14 Global Lung Cancer Liquid Biopsy Market Segmentation

  • 14.1 Global Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 14.2 Global Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 14.3 Global Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 14.4 Global Lung Cancer Liquid Biopsy Market, Segmentation By Clinical Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 14.5 Global Lung Cancer Liquid Biopsy Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 14.6 Global Lung Cancer Liquid Biopsy Market, Sub-Segmentation Of Instruments, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 14.7 Global Lung Cancer Liquid Biopsy Market, Sub-Segmentation Of Consumables, Kits And Reagents, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 14.8 Global Lung Cancer Liquid Biopsy Market, Sub-Segmentation Of Software And Services, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

15 Lung Cancer Liquid Biopsy Market, Regional and Country Analysis

  • 15.1 Global Lung Cancer Liquid Biopsy Market, By Region, Historic and Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 15.2 Global Lung Cancer Liquid Biopsy Market, By Country, Historic and Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

16 Asia-Pacific Market

  • 16.1 Asia-Pacific Market Summary
  • 16.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
  • 16.3 Asia-Pacific Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 16.4 Asia-Pacific Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 16.5 Asia-Pacific Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 16.6 China Market
    • 16.6.1 China Market Summary
    • 16.6.2 Market Overview (Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
    • 16.6.3 China Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.6.4 China Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.6.5 China Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 16.7 India Market
    • 16.7.1 India Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.7.2 India Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.7.3 India Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 16.8 Japan Market
    • 16.8.1 Japan Market Summary
    • 16.8.2 Market Overview (Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
    • 16.8.3 Japan Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.8.4 Japan Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.8.5 Japan Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 16.9 Australia Market
    • 16.9.1 Australia Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.9.2 Australia Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.9.3 Australia Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 16.10 South Korea Market
    • 16.10.1 South Korea Market Summary
    • 16.10.2 Market Overview (Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
    • 16.10.3 South Korea Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.10.4 South Korea Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.10.5 South Korea Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 16.11 Taiwan Market
    • 16.11.1 Taiwan Market Summary
    • 16.11.2 Market Overview (Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
    • 16.11.3 Taiwan Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.11.4 Taiwan Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.11.5 Taiwan Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

17 South East Asia Market

  • 17.1 South East Asia Market Summary
  • 17.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
    • 17.2.1 South East Asia Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 17.2.2 South East Asia Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 17.2.3 South East Asia Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 17.3 Indonesia Market
    • 17.3.1 Indonesia Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 17.3.2 Indonesia Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 17.3.3 Indonesia Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

18 North America Market

  • 18.1 North America Market Summary
  • 18.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
  • 18.3 North America Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 18.4 North America Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 18.5 North America Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 18.6 USA Market
    • 18.6.1 USA Market Summary
    • 18.6.2 Market Overview (Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
    • 18.6.3 USA Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 18.6.4 USA Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 18.6.5 USA Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 18.7 Canada Market
    • 18.7.1 Canada Market Summary
    • 18.7.2 Market Overview (Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
    • 18.7.3 Canada Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 18.7.4 Canada Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 18.7.5 Canada Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

19 Western Europe Market

  • 19.1 Western Europe Market Summary
  • 19.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
  • 19.3 Western Europe Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 19.4 Western Europe Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 19.5 Western Europe Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 19.6 UK Market
    • 19.6.1 UK Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 19.6.2 UK Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 19.6.3 UK Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 19.7 Germany Market
    • 19.7.1 Germany Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 19.7.2 Germany Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 19.7.3 Germany Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 19.8 France Market
    • 19.8.1 France Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 19.8.2 France Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 19.8.3 France Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 19.9 Italy Market
    • 19.9.1 Italy Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 19.9.2 Italy Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 19.9.3 Italy Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 19.10 Spain Market
    • 19.10.1 Spain Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 19.10.2 Spain Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 19.10.3 Spain Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

20 South America Market

  • 20.1 South America Market Summary
  • 20.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure And Major Companies)
  • 20.3 South America Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 20.4 South America Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 20.5 South America Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 20.6 Brazil Market
    • 20.6.1 Brazil Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 20.6.2 Brazil Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 20.6.3 Brazil Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

21 Eastern Europe Market

  • 21.1 Eastern Europe Market Summary
  • 21.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure And Major Companies)
  • 21.3 Eastern Europe Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 21.4 Eastern Europe Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 21.5 Eastern Europe Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 21.6 Russia Market
    • 21.6.1 Russia Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 21.6.2 Russia Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 21.6.3 Russia Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

22 Middle East Market

  • 22.1 Middle East Market Summary
  • 22.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
  • 22.3 Middle East Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 22.4 Middle East Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 22.5 Middle East Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

23 Africa Market

  • 23.1 Africa Market Summary
  • 23.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure And Major Companies)
  • 23.3 Africa Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 23.4 Africa Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 23.5 Africa Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

24 Competitive Landscape And Company Profiles

  • 24.1 Lung Cancer Liquid Biopsy Market Competitive Landscape And Market Share 2024
    • 24.1.1 Top 10 Companies (Ranked by revenue/share)
  • 24.2 Company Profiles
  • 24.3 F. Hoffmann-La Roche Ltd (Company Overview, Products and Services, Business Strategy, Financial Overview)
  • 24.4 Qiagen N.V. (Company Overview, Products and Services, Business Strategy, Financial Overview)
  • 24.5 Guardant Health Inc (Company Overview, Products and Services, Business Strategy, Financial Overview)
  • 24.6 Thermo Fisher Scientific Inc (Company Overview, Products and Services, Business Strategy, Financial Overview)
  • 24.7 Eurofins Scientific SE (Company Overview, Products and Services, Business Strategy, Financial Overview)

25 Other Major And Innovative Companies

  • 25.1 NeoGenomics Laboratories Inc. (Company Overview | Products and Services)
  • 25.2 Agilent Technologies Inc. (Company Overview | Products and Services)
  • 25.3 Sysmex Corporation (Company Overview | Products and Services)
  • 25.4 Illumina Inc. (Company Overview | Products and Services)
  • 25.5 Biodesix Inc. (Company Overview | Products and Services)
  • 25.6 SOPHiA GENETICS SA (Company Overview | Products and Services)
  • 25.7 Caris Life Sciences Inc. (Company Overview | Products and Services)
  • 25.8 Natera Inc. (Company Overview | Products and Services)
  • 25.9 Bio-Rad Laboratories Inc. (Company Overview | Products and Services)
  • 25.10 MDxHealth SA (Company Overview | Products and Services)
  • 25.11 Foresight Diagnostics Inc. (Company Overview | Products and Services)
  • 25.12 Myriad Genetics Inc. (Company Overview | Products and Services)
  • 25.13 Menarini Silicon Biosystems Inc. (Company Overview | Products and Services)
  • 25.14 Inivata Ltd. (Company Overview | Products and Services)
  • 25.15 LungLife AI Inc. (Company Overview | Products and Services)

26 Competitive Benchmarking

27 Competitive Dashboard

28 Lung Cancer Liquid Biopsy Market - Company Scoring Matrix

  • 28.1 Innovation & Brand Leaders
  • 28.2 Brand-Driven Traditionalists
  • 28.3 Niche or Regional Followers
  • 28.4 Emerging Innovators

29 Upcoming Startups In the Lung Cancer Liquid Biopsy Market

30 Key Mergers And Acquisitions

  • 30.1 Abbott Laboratories Acquired Exact Sciences Corporation
  • 30.2 Veracyte Inc Acquired C2i Genomics Inc
  • 30.3 Quest Diagnostics Acquired Haystack Oncology

31 Recent Developments In Lung Cancer Liquid Biopsy

  • 31.1 Strengthening Precision Oncology Through Advanced Liquid Biopsy Integration In Clinical Research
  • 31.2 Development Of Updated Platforms To Provide Advanced Cancer Profiling

32 Opportunities And Strategies

  • 32.1 Global Lung Cancer Liquid Biopsy Market In 2030 - Countries Offering Most New Opportunities
  • 32.2 Global Lung Cancer Liquid Biopsy Market In 2030 - Segments Offering Most New Opportunities
  • 32.3 Global Lung Cancer Liquid Biopsy Market In 2030 - Growth Strategies
    • 32.3.1 Market Trend Based Strategies
    • 32.3.2 Competitor Strategies

33 Lung Cancer Liquid Biopsy Market, Conclusions And Recommendations

  • 33.1 Conclusions
  • 33.2 Recommendations
    • 33.2.1 Product
    • 33.2.2 Place
    • 33.2.3 Price
    • 33.2.4 Promotion
    • 33.2.5 People

34 Appendix

  • 34.1 Geographies Covered
  • 34.2 Market Data Sources
  • 34.3 Research Methodology
  • 34.4 Currencies
  • 34.5 The Business Research Company
  • 34.6 Copyright and Disclaimer